EVT planning to restart EndoVascular Grafting System trials by year-end.
This article was originally published in The Gray Sheet
Executive SummaryENDOVASCULAR TECHNOLOGIES ENDOVASCULAR GRAFTING SYSTEM CLINICALS are expected to recommence before the end of 1995, company President and CEO Jim Fitzsimmons said at a May 16 session of the Alex. Brown & Sons Health Care Seminar in Baltimore. Earlier this year, the privately held company voluntarily suspended two trials following discovery of breaks in the attachment component of the grafting system ("The Gray Sheet" Feb. 27, p. 13). The suspended studies -- a Phase II trial of the EndoGraft tube vascular graft implant and a Phase I study of the bifurcated EndoGraft -- were evaluating the systems in the treatment of abdominal aortic aneurysms.
You may also be interested in...
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.
At the OurCrowd Global Investor Summit in Jerusalem, Israel, on 13 February, Medtech Insight met wound care device company Nanomedic to find out more about its unique electro-spinning technology.